Mylan Launches Generic Version of Qualaquin Caps
Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This
product is the generic version of Mutual Pharmaceutical Company, Inc.'s
Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment
of uncomplicated Plasmodium falciparum malaria.(1)
Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9
million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Mylan has begun shipping this product.